Paige vs Proscia
The algorithm that created the category against the platform it runs on. Paige holds the first authorization for an AI based digital pathology product, obtained through the De Novo route, which established the regulatory path everything since has used, with authorised depth in prostate cancer detection. Proscia manages and analyses whole slide data for clinical laboratories and life sciences customers, with the deeper Western installed base. A laboratory going digital needs the platform before it needs any particular detector, and then needs detectors worth running on it, so these are sequential rather than competing purchases. Neither publishes performance across the staining and scanner variation that differs between laboratories, which affects the algorithm far more than the platform.
- It produced the first authorization for an AI based digital pathology product through the De Novo route, which created the regulatory category the rest of the lane files into.
- Authorised depth in prostate cancer detection means the capability was reviewed rather than demonstrated.
- Foundation model scale work sits behind the broader ambition rather than only a fixed detector set.
- The platform manages and analyses whole slide data for clinical laboratories and life sciences customers at established scale, with the deeper Western installed base.
- Serving diagnostic work and research contracts on the same infrastructure spreads the investment across two budgets.
- For a laboratory going digital at all, the platform comes first and algorithms run on top of it.
Side by Side
| Axis | P Paige |
P Proscia |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
These sit at different layers and a laboratory may well need both, since one supplies an authorised detection capability and the other supplies the slide management platform algorithms run on. Neither publishes pricing. Neither publishes subgroup or site level performance, and staining and scanner variation between laboratories remains the largest uncontrolled variable for any model either runs, which matters more for the algorithm than for the platform.